Grifols S.A. Total Assets
Grifols S.A. total assets. Based on the latest financial reports, Grifols S.A. (GRF) holds total assets worth €19.77 Billion EUR (≈ $23.11 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Grifols S.A. (GRF) cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Grifols S.A. (2005–2024)
Total assets of Grifols S.A. from 2005 to 2024. This chart illustrates how Grifols S.A.'s total assets have evolved over time, based on quarterly financial data. See GRF stock price for real-time trading data and today's change.
Grifols S.A. - Asset Composition Analysis
Grifols S.A. Total Assets Breakdown (December 2024)
Grifols S.A. total assets breakdown as of December 2024. Grifols S.A.'s total assets of €19.77 Billion consist of 26.8% current assets and 73.2% non-current assets. Explore GRF current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.6% |
| Accounts Receivable | €741.43 Million | 3.5% |
| Inventory | €3.56 Billion | 16.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.93 Billion | 13.7% |
| Goodwill | €7.40 Billion | 34.6% |
Asset Composition Trend (2005–2024)
This chart illustrates how Grifols S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Grifols S.A.'s current assets represent 26.8% of total assets in 2024, a decrease from 53.1% in 2005.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2024, up from 2.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 19.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 34.6% of total assets.
Grifols S.A. Competitors by Total Assets
Key competitors of Grifols S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
|
Roche Holding AG
SW:ROP
|
Switzerland | CHF100.70 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Yung Zip Chemical Ind Co Ltd
TWO:4102
|
Taiwan | NT$927.10 Million |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
Grifols S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.64 | 1.68 | 2.86 |
| Quick Ratio | 0.95 | 0.80 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.26 Billion | €2.80 Billion | €2.31 Billion |
Grifols S.A. - Advanced Valuation Insights
This section examines the relationship between Grifols S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | €21.41 Billion |
| Market Capitalization | $5.42 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Grifols S.A.'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Grifols S.A.'s assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Grifols S.A. (2005–2024)
The table below shows the annual total assets of Grifols S.A. from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €21.41 Billion ≈ $25.02 Billion |
-0.17% |
| 2023-12-31 | €21.44 Billion ≈ $25.07 Billion |
-0.43% |
| 2022-12-31 | €21.53 Billion ≈ $25.18 Billion |
+11.96% |
| 2021-12-31 | €19.23 Billion ≈ $22.49 Billion |
+25.92% |
| 2020-12-31 | €15.27 Billion ≈ $17.86 Billion |
-1.72% |
| 2019-12-31 | €15.54 Billion ≈ $18.17 Billion |
+24.57% |
| 2018-12-31 | €12.48 Billion ≈ $14.59 Billion |
+14.26% |
| 2017-12-31 | €10.92 Billion ≈ $12.77 Billion |
+7.80% |
| 2016-12-31 | €10.13 Billion ≈ $11.84 Billion |
+5.50% |
| 2015-12-31 | €9.60 Billion ≈ $11.23 Billion |
+13.63% |
| 2014-12-31 | €8.45 Billion ≈ $9.88 Billion |
+44.66% |
| 2013-12-31 | €5.84 Billion ≈ $6.83 Billion |
+3.79% |
| 2012-12-31 | €5.63 Billion ≈ $6.58 Billion |
-3.10% |
| 2011-12-31 | €5.81 Billion ≈ $6.79 Billion |
+207.45% |
| 2010-12-31 | €1.89 Billion ≈ $2.21 Billion |
+13.99% |
| 2009-12-31 | €1.66 Billion ≈ $1.94 Billion |
+40.41% |
| 2008-12-31 | €1.18 Billion ≈ $1.38 Billion |
+25.61% |
| 2007-12-31 | €939.57 Million ≈ $1.10 Billion |
+2.83% |
| 2006-12-31 | €913.67 Million ≈ $1.07 Billion |
+11.20% |
| 2005-12-31 | €821.68 Million ≈ $960.63 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more